Multiple endocrine neoplasia type 4

Endocrine Tumor Syndromes and Their Genetics

Volumn 41, Issue , 2013, Pages 66-78

  Lee, Misu ^a   Pellegata, Natalia S ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877967788     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000345670     Document Type: Chapter

References (35)

1. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck- Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Man- nelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, To- massetti P, Tonelli F, Wells SA Jr, Marx SJ: Guide- lines for diagnosis and therapy of men type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-5671.
2. Marx SJ: Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 2005;5: 367-375.
3. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H, Fend F, Graw J, At- kinson MJ: Germ-line mutations in p27kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 2006;103:15558-15563.
4. Costa-Guda J, Marinoni I, Molatore S, Pellegata NS, Arnold A: Somatic mutation and germline se- quence abnormalities in cdkn1b, encoding p27kip1, in sporadic parathyroid adenomas. J Clin Endocri- nol Metab 2011;96:E701-E706.
5. Thakker RV: Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab 2010;24:355-370.
6. Marx SJ: Hyperparathyroid genes: sequences reveal answers and questions. Endocr Pract 2011;3:18-27.
7. Melmed S: Mechanisms for pituitary tumorigene- sis: the plastic pituitary. J Clin Invest 2003;112: 1603-1618.
8. Rothenbuhler A, Stratakis CA: Clinical and molec- ular genetics of Carney complex. Best Pract Res Clin Endocrinol Metab 2010;24:389-399.
9. Daly AF, Tichomirowa MA, Beckers A: The epide- miology and genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 2009;23:543-554.
10. Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C, Calender A: Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002 87:457-465.
11. Platta CS, Mackay C, Welsh JS: Pituitary adenoma: a radiotherapeutic perspective. Am J Clin Oncol 2010;33:408-419.
12. Hofland LJ, Feelders RA, de Herder WW, Lamberts SW: Pituitary tumours: the sst/d2 receptors as mo- lecular targets. Mol Cell Endocrinol 2010;326:89-98.
13. Debelenko LV, Brambilla E, Agarwal SK, Swalwell JI, Kester MB, Lubensky IA, Zhuang Z, Guru SC, Manickam P, Olufemi SE, Chandrasekharappa SC, Crabtree JS, Kim YS, Heppner C, Burns AL, Spiegel AM, Marx SJ, Liotta LA, Collins FS, Travis WD, Emmert-Buck MR: Identification of men1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet 1997;6:2285-2290.
14. Fritz A, Walch A, Piotrowska K, Rosemann M, Schaffer E, Weber K, Timper A, Wildner G, Graw J, Hofler H, Atkinson MJ: Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res. 2002;62:3048-3051.
15. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(kip1)-de- ficient mice. Cell 1996;85:733-744.
16. Morosetti R, Kawamata N, Gombart AF, Miller CW, Hatta Y, Hirama T, Said JW, Tomonaga M, Koeffler HP: Alterations of the p27kip1 gene in non-hodgkin's lymphomas and adult T-cell leuke- mia/lymphoma. Blood 1995;86:1924-1930.
17. Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW, Koeffler HP: P27/kip1 mutation found in breast cancer. Cancer Res 1996;56:2400-2404.
18. Pappa V, Papageorgiou S, Papageorgiou E, Panani A, Boutou E, Tsirigotis P, Dervenoulas J, Economo- poulos T, Raptis S: A novel p27 gene mutation in a case of unclassified myeloproliferative disorder. Leukemia Res. 2005;29:229-231.
19. Pasquali D, Circelli L, Faggiano A, Pancione M, Renzullo A, Elisei R, Romei C, Accardo G, Coppola VR, De Palma M, Ferolla P, Grimaldi F, Colao A, Colantuoni V: Cdkn1b v109g polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma. Eur J Endocrinol 2011;164:397-404.
20. Landa I, Montero-Conde C, Malanga D, De Gisi S, Pita G, Leandro-Garcia LJ, Inglada-Perez L, Leton R, De Marco C, Rodriguez-Antona C, Viglietto G, Robledo M: Allelic variant at -79 (c>t) in cdkn1b (p27kip1) confers an increased risk o thyroid can- cer and alters mRNA levels. Endocr Relat Cancer 2010;17:317-328.
21. Malanga D, De Gisi S, Riccardi M, Scrima M, De Marco C, Robledo M, Viglietto G: Functional char- acterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27kip1 (cdkn1b) in a Spanish patien with multiple endocrine neoplasia-like phenotype. Eur J Endocri- nol 2012;166:551-560.
22. Agarwal SK, Mateo CM, Marx SJ: Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab 2009;94: 1826-1834.
23. Georgitsi M, Raitila A, Karhu A, et al. Germline cd- kn1b/p27kip1 mutation in multiple endocrine neo- plasia. J Clin Endocrinol Metab 2007;92:3321-3325.
24. Belar O, De La Hoz C, Perez-Nanclares G, Castano L, Gaztambide S: Novel mutations in MEN1, CD- KN1B and AIP genes in patients with multiple en- docrine neoplasia type 1 syndrome in Spain. Clin Endocrinol 2012;76:719-724.
25. Molatore S, Marinoni I, Lee M, Pulz E, Ambrosio MR, degli Uberti EC, Zatelli MC, Pellegata NS: A novel germline CDKN1B mutation causing multi- ple endocrine tumors: clinical, genetic and func- tional characterization. Hum Mut 2010;31:E1825-E1835.
26. Tichomirowa MA, Lee M, Barlier A, et al. Cyclin- dependent kinase inhibitor 1b (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. Endocr Relat Cancer 2012;19:233-241.
27. Marinoni I, Pellegata NS: p27kip1: a new multiple endocrine neoplasia gene? Neuroendocrinology 2011;93:19-28.
28. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-1512.
29. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome pathway in regu- lating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-685.
30. Kamura T, Hara T, Matsumoto M, Ishida N, Oku- mura F, Hatakeyama S, Yoshida M, Nakayama K, Nakayama KI: Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(kip1) at G1 phase. Nat Cell Biol 2004;6:1229-1235.
31. Carrano AC, Eytan E, Hershko A, Pagano M: Skp2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193-199.
32. Besson A, Hwang HC, Cicero S, Donovan SL, Guri- an-West M, Johnson D, Clurman BE, Dyer MA, Roberts JM: Discovery of an oncogenic activity in p27kip1 that causes stem cell expansion and a mul- tiple tumor phenotype. Genes Dev 2007;21:1731-1746.
33. Chu IM, Hengst L, Slingerland JM: The CDK in- hibitor p27 in human cancer: Prognostic potential and relevance to anticancer therapy. Nat Rev Can- cer 2008;8:253-267.
34. Molatore S, Kiermaier E, Jung CB, Pulz E, Höfler H, Atkinson MJ, Pellegata NS: Characterization of a naturally-occurring p27 mutation predisposing to multiple endocrine tumors. Mol Cancer 2010;9:116.
35. Payne SR, Kemp CJ: P27(kip1) (CDKN1B)-deficient mice are susceptible to chemical carcinogenesis and may be a useful model for carcinogen screening. Toxicol Pathol 2003;31:355-363.